Abivax shares drop 27% over three months and slip to the tail of the SBF 120
The Paris-based biotech specialising in inflammatory diseases is in negative territory mid-morning, in a Paris market trending lower. The move extends a difficult quarter and leaves the stock far from its long-term reference levels, while short positions remain in place.
A stock below its three moving averages after a quarter at -27%
Abivax shares fell 2.8% to €74.75 during the session, while the CAC 40 declined 1.06%, and the stock ranks among the largest decliners in the SBF 120. It has lost 27.2% over three months and remains below its three moving averages: the MM20 is at €79.38, 5.8% above the price, and the MM200 at €97.79.
The price has fallen back below €76.05, the lowest level of the last 30 sessions, which has been broken to the downside and has become resistance. Analyst opinions are not included in this item, which is limited to price levels.
Abivax is a single company listed on two exchanges: the ordinary share in Paris, eligible for the PEA, and the ADS on the Nasdaq, which represents the same security on a one-for-one ratio. Both lines quote the same price in real time.
Five funds hold 5.59% of the capital in net short position
According to the declarations reviewed, five funds together hold a net short position of 5.59% of the capital, up 0.24 points over thirty days. This level is high: it shows that institutional investors remain positioned against the stock or are seeking to hedge an exposure.
The increase over one month remains moderate and does not, on its own, reflect a massive lack of confidence, but the point deserves to be monitored alongside the price.
The stock had already fallen back below €76.05 on Monday. The session is taking place in a context of heightened volatility, with the VIX gaining nearly 23%. The €76.05 level is now the nearest resistance, and the €63.10 support is the next threshold below the price.